---
document_datetime: 2023-09-21 17:57:24
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-teva-pharma-bv-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-teva-pharma-bv-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3095781
conversion_datetime: 2025-12-19 03:34:06.623296
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Clopidogrel Teva Pharma B.V.

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended Product Information affected 3 no   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------------------------------------------------------------------|-----------|
| IB/0009/G            | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a Medicinal | 15/05/2014 product                  | on SmPC and PL                                                             |           |

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                     |                                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| IB/0007   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                   | 10/02/2014 SmPC and PL authorised           |
| IB/0006/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal product | 10/10/2013 SmPC and PL no longer            |
| IB/0005/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference                                                                                                                                                                                                                                                                                                                                                                                              | 15/08/2013 SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                        | authorised                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| IA/0004/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites C.I.z - Changes (Safety/Efficacy) of Human and | 21/05/2013 Annex no longer  |
| IB/0003   | Veterinary Medicinal Products - Other variation B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                             | 04/06/2012 n/a SmPC product |
| IA/0002   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) Medicinal                                                                                                                                                                                                                     | 18/11/2011 n/a              |
| IB/0001/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                    | 04/11/2011 n/a SmPC,        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH

## Medicinal product no longer authorised